Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Active:	Yes
Cancer Type:	Breast Cancer Cervical Cancer Esophogeal Cancer Lung Cancer Ovarian Cancer Stomach/ Gastric Cancer	NCT ID:	NCT06293898
Trial Phases:	Phase I	Protocol IDs:	BL-M07D1-ST-101 (primary) NCI-2024-07363
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	SystImmune Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT06293898

Summary

The objective of this study is to evaluate the safety, tolerability, and efficacy of
BL-M07D1 in patients with HER2 expressing advanced tumors.

Objectives

BL-M07D1-ST-101 is a global, multi-center, Phase 1 study to evaluate the safety,
tolerability, pharmacokinetics, and efficacy of BL-M07D1 in participants with HER2
expressing advanced malignant solid tumors.

This study will be conducted in three parts (dose escalation, dose finding and dose
expansion). Dosing will be conducted on Day 1 of a continuous 21-day treatment cycle. .

Treatment Sites in Georgia

Georgia Cancer Center at Augusta University
1411 Laney Walker Boulevard
Augusta, GA 30912
www.augusta.edu/cancer/

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.